These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 25586468)

  • 1. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
    Schuster J; Lai RK; Recht LD; Reardon DA; Paleologos NA; Groves MD; Mrugala MM; Jensen R; Baehring JM; Sloan A; Archer GE; Bigner DD; Cruickshank S; Green JA; Keler T; Davis TA; Heimberger AB; Sampson JH
    Neuro Oncol; 2015 Jun; 17(6):854-61. PubMed ID: 25586468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospect of rindopepimut in the treatment of glioblastoma.
    Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
    Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
    Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
    J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
    Del Vecchio CA; Wong AJ
    Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
    Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
    Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
    Reardon DA; Desjardins A; Vredenburgh JJ; O'Rourke DM; Tran DD; Fink KL; Nabors LB; Li G; Bota DA; Lukas RV; Ashby LS; Duic JP; Mrugala MM; Cruickshank S; Vitale L; He Y; Green JA; Yellin MJ; Turner CD; Keler T; Davis TA; Sampson JH;
    Clin Cancer Res; 2020 Apr; 26(7):1586-1594. PubMed ID: 32034072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
    Weller M; Kaulich K; Hentschel B; Felsberg J; Gramatzki D; Pietsch T; Simon M; Westphal M; Schackert G; Tonn JC; von Deimling A; Davis T; Weiss WA; Loeffler M; Reifenberger G;
    Int J Cancer; 2014 May; 134(10):2437-47. PubMed ID: 24614983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
    Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
    Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
    Reardon DA; Lassman AB; van den Bent M; Kumthekar P; Merrell R; Scott AM; Fichtel L; Sulman EP; Gomez E; Fischer J; Lee HJ; Munasinghe W; Xiong H; Mandich H; Roberts-Rapp L; Ansell P; Holen KD; Gan HK
    Neuro Oncol; 2017 Jul; 19(7):965-975. PubMed ID: 28039367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
    Nabors LB; Fiveash JB; Markert JM; Kekan MS; Gillespie GY; Huang Z; Johnson MJ; Meleth S; Kuo H; Gladson CL; Fathallah-Shaykh HM
    Arch Neurol; 2010 Mar; 67(3):313-9. PubMed ID: 20212229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.
    Gedeon PC; Choi BD; Sampson JH; Bigner DD
    Drugs Future; 2013 Mar; 38(3):147-155. PubMed ID: 25663738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.
    Babu R; Adamson DC
    Core Evid; 2012; 7():93-103. PubMed ID: 23055947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
    Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
    Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
    Li L; Quang TS; Gracely EJ; Kim JH; Emrich JG; Yaeger TE; Jenrette JM; Cohen SC; Black P; Brady LW
    J Neurosurg; 2010 Aug; 113(2):192-8. PubMed ID: 20345222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
    Gatson NT; Weathers SP; de Groot JF
    CNS Oncol; 2016; 5(1):11-26. PubMed ID: 26670466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.